Moloxin (Moxifloxacin)

Moxifloxacin, the active ingredient in Moloxin, is a fluoroquinolone presented as an intravenous injection for intravenous use. It treats adult patients with community‑acquired pneumonia, acute bacterial sinusitis, complicated skin and skin‑structure infections, and complicated intra‑abdominal infections.

GNH USA supplies Moloxin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable cold‑chain logistics for injectable products. Moloxin is distributed to acute care facilities and specialty centers seeking broad‑spectrum antibacterial therapy.

Moloxin (moxifloxacin) is used to treat bacterial infections affecting the respiratory, sinus, skin and intra‑abdominal systems. - Community‑acquired pneumonia: provides bacterial eradication and clinical improvement in adult patients. - Acute bacterial sinusitis: reduces symptoms and accelerates resolution of infection. - Complicated skin and skin‑structure infections: achieves effective coverage of Gram‑negative and Gram‑positive pathogens. - Complicated intra‑abdominal infections: offers broad‑spectrum activity for polymicrobial abdominal sepsis.

Moxifloxacin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, usually self‑limiting. - Headache: transient cranial discomfort. - Elevated liver enzymes: mild, reversible transaminase rise.

Serious or Rare Side Effects: - Tendon rupture: risk of Achilles or other tendon injury, especially in older adults. - QT interval prolongation: may precipitate cardiac arrhythmias. - Severe hypersensitivity: including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Clostridioides difficile infection: possible colitis following disruption of gut flora.

Before initiating Moloxin, clinicians should evaluate patient‑specific factors and adhere to safety guidelines. - Renal impairment: adjust therapy based on renal function and monitor for accumulation. - Hepatic dysfunction: use with caution; monitor liver function tests. - Concomitant QT‑prolonging drugs: avoid or monitor ECG for arrhythmia risk. - History of tendon disorders: avoid use in patients with prior tendon injury or recent corticosteroid therapy. - Pregnancy and lactation: safety not established; prescribe only if benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption; separate dosing by at least 2 hours. - Warfarin: may increase INR; monitor coagulation parameters closely. - Theophylline: increased plasma levels; observe for toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of CNS stimulation. - Cyclosporine: higher moxifloxacin concentrations; monitor renal function. - Oral hypoglycemics (e.g., sulfonylureas): potential for enhanced hypoglycemia; check blood glucose.